Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients
Рекомендации по диагностике, клинической оценке, лечению и ведению пациентов с заболеванием CLN2
2021-04-21
SCID: 54.1/k3cpt4ae
Discuss with AI
CLN2 diseaselysosomal storage diseasemodified Delphi consensusneuronal ceroid lipofuscinosis type 2tripeptidyl peptidase 1
Figures from the paper
Abstract (AI)
BACKGROUND: CLN2 disease (Neuronal Ceroid Lipofuscinosis Type 2) is an ultra-rare, neurodegenerative lysosomal storage disease, caused by an enzyme deficiency of tripeptidyl peptidase 1 (TPP1). Lack of disease awareness and the non-specificity of presenting symptoms often leads to delayed diagnosis. These guidelines provide robust evidence-based, expert-agreed recommendations on the risks/benefits of disease-modifying treatments and the medical interventions used to manage this condition. METHODS: An expert mapping tool process was developed ranking multidisciplinary professionals, with knowledge of CLN2 disease, diagnostic or management experience of CLN2 disease, or family support professionals. Individuals were sequentially approached to identify two chairs, ensuring that the process was transparent and unbiased. A systematic literature review of published evidence using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance was independently and simultaneously conducted to develop key statements based upon the strength of the publications. Clinical care statements formed the basis of an international modified Delphi consensus determination process using the virtual meeting (Within3) online platform which requested experts to agree or disagree with any changes. Statements reaching the consensus mark became the guiding statements within this manuscript, which were subsequently assessed against the Appraisal of Guidelines for Research and Evaluation (AGREEII) criteria. RESULTS: Twenty-one international experts from 7 different specialities, including a patient advocate, were identified. Fifty-three guideline statements were developed covering 13 domains: General Description and Statements, Diagnostics, Clinical Recommendations and Management, Assessments, Interventions and Treatment, Additional Care Considerations, Social Care Considerations, Pain Management, Epilepsy / Seizures, Nutritional Care Interventions, Respiratory Health, Sleep and Rest, and End of Life Care. Consensus was reached after a single round of voting, with one exception which was revised, and agreed by 100% of the SC and achieved 80% consensus in the second voting round. The overall AGREE II assessment score obtained for the development of the guidelines was 5.7 (where 1 represents the lowest quality, and 7 represents the highest quality). CONCLUSION: This program provides robust evidence- and consensus-driven guidelines that can be used by all healthcare professionals involved in the management of patients with CLN2 disease and other neurodegenerative disorders. This addresses the clinical need to complement other information available.
Key Findings
1
Fifty-three consensus guideline statements were established across 13 domains, covering diagnosis, clinical assessments, disease-modifying treatment, symptom management, and multidisciplinary supportive care.
2
International guidelines for CLN2 disease were developed through a systematic literature review and modified Delphi consensus involving 21 experts from seven specialties, including a patient advocate.
3
Recommendations address risks and benefits of disease-modifying treatments alongside interventions for epilepsy, nutrition, respiratory health, pain, and social care.
4
The guideline development process was assessed using AGREE II criteria to support methodological quality and transparency.
5
The guidelines address delayed diagnosis caused by limited disease awareness and nonspecific presenting symptoms in this ultra-rare TPP1-deficiency disorder.
Research Object
CLN2 disease patients and their diagnosis, treatment, and clinical management
Research Subject
Evidence-based and expert-consensus recommendations for diagnosing, assessing, treating, and managing CLN2 disease, including disease-modifying therapy and supportive care
Publication Details
Publication Date
2021-04-21
Journal
Publisher
ISSN
Cited by
66
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai7
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement2009
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement2009
Management Strategies for CLN2 Disease2017
Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis2016
Molecular epidemiology of childhood neuronal ceroid-lipofuscinosis in Italy2013
Spectrum of Ocular Manifestations in CLN2-Associated Batten (Jansky-Bielschowsky) Disease Correlate with Advancing Age and Deteriorating Neurological Function2013
Experiences with Cannabidiol in Patients with NCL Disease2019